Imatinib plus Granulocyte Colony-Stimulating Factor in Chronic Myeloid Leukemia Patients Who Have Achieved Partial or Complete Cytogenetic Response while on Imatinib

BACKGROUND: The BCR/ABL tyrosine kinase inhibitor imatinib is highly effective in the treatment of chronic myeloid leukemia (CML) but fails to eliminate all leukemia cells. In this study, we investigated whether the addition of granulocyte colony-stimulating factor (G-CSF) could reduce the level of...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Baijun, Mai, Ling, Li, Ning, Song, Yongping, Chunhua Zhao, Robert
Formato: Texto
Lenguaje:English
Publicado: S. Karger AG 2011
Materias:
Published online: April 2011
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080784/
https://www.ncbi.nlm.nih.gov/pubmed/21516268
http://dx.doi.org/10.1159/000327512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080784/
https://www.ncbi.nlm.nih.gov/pubmed/21516268
http://dx.doi.org/10.1159/000327512

Ejemplares similares